Inhibrx Biosciences (INBX) Stock: Buy, Sell, or Hold?
INBX - Inhibrx Biosciences, Inc. Common Stock
$97.93
-2.15 (-2.15%)
▼
5d:
-2.46%
30d:
-21.44%
90d:
+0.36%
HOLD
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When INBX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INBX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: INBX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: INBX is currently trading at $97.93, which is considered oversold relative to its 30-day fair value range of $102.26 to $121.13.
Technical Outlook: Technically, INBX is showing sideways momentum. The price is currently testing key support at $97.58. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INBX scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (22th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $266.67 (+172.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INBX is showing sideways momentum. The price is currently testing key support at $97.58. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INBX scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (22th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $266.67 (+172.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$102.26 -
$121.13
Company Quality Score
57/100
(HOLD)
Options IV Signal
22th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
95.8%
Protect Your Profits
Holding INBX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 22th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 172.3% below Wall St target ($266.67)
- CAUTION: Bottoming setup, but lagging the sector by 34% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$102.26 -
$121.13
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$14.29
(14.6%)
Support & Resistance Levels
Support Level
$97.58
Resistance Level
$117.14
Current Trend
Sideways
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.18
Wall Street Target
$266.67
(+172.3%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 02, 2026 4:43 AM ET
Data refreshes hourly during market hours. Next update: 5:43 AM
Data refreshes hourly during market hours. Next update: 5:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INBX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 63 BUY |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 55 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 57 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 70 BUY |
Advanced INBX Option Strategies
Professional options setups generated by AI based on today's INBX price and gamma walls.
